Triple-negative breast cancer lacks an expression of ER, PR, and Her-2, has a poor prognosis, and there are no target therapies available. Therapeutic options to treat TNBC are limited and urgently needed. Strong evidence indicates that molecular signaling pathways have a significant function to regulate biological mechanisms and their abnormal expression endows with the development of cancer. PIM kinase is overexpressed in various human cancers including TNBC which is regulated by various signaling pathways that are crucial for cancer cell proliferation and survival and also make PIM kinase as an attractive drug target. One of the targets of the STAT3 signaling pathway is PIM1 that plays a key role in tumor progression and transformation. In this review, we accumulate the current scenario of the PIM-STAT3 axis that provides insights into the PIM1 and STAT3 inhibitors which can be developed as potential co-inhibitors as prospective anticancer agents.

三阴性乳腺癌缺乏ER、PR和Her-2的表达，预后较差，并且没有可用的靶向疗法。治疗 TNBC 的治疗选择有限且迫切需要。强有力的证据表明，分子信号通路具有调节生物学机制的重要功能，其异常表达与癌症的发展有关。PIM 激酶在包括 TNBC 在内的各种人类癌症中过表达，TNBC 受各种信号通路调节，这些信号通路对癌细胞增殖和存活至关重要，也使 PIM 激酶成为有吸引力的药物靶点。STAT3 信号通路的靶点之一是在肿瘤进展和转化中起关键作用的 PIM1。在本次审查中，